menu search

FLHLF / Filament Health JV Magdalena Biosciences kicks off preclinical study of plant extracts for mental health indications

Filament Health JV Magdalena Biosciences kicks off preclinical study of plant extracts for mental health indications
Filament Health Corp (OTCQB:FLHLF, NEO:FH) said Magdalena Biosciences, its joint venture (JV) with Jaguar Health, has initiated a preclinical study of two plant extracts for their potential therapeutic use in depression, anxiety, attention-deficit/hyperactivity disorder (ADHD) and other neuropsychiatric conditions initially in adults. The preclinical study will evaluate both extracts in mice using fluorodeoxyglucose positron emission tomography (FDG PET) scans to look for differential neuronal activity, the company said. Read More
Posted: Oct 23 2023, 09:03
Author Name: Proactive Investors
Views: 091999

FLHLF News  

Filament Health's expertise positions it to tap into multi-billion psychedelics opportunity

By Proactive Investors
October 31, 2023

Filament Health's expertise positions it to tap into multi-billion psychedelics opportunity

Analysts at Water Tower Research have initiated coverage on Filament Health Corp (OTCQB:FLHLF, NEO:FH) with a positive outlook on the firm which they more_horizontal

Filament Health JV Magdalena Biosciences kicks off preclinical study of plant extracts for mental health indications

By Proactive Investors
October 23, 2023

Filament Health JV Magdalena Biosciences kicks off preclinical study of plant extracts for mental health indications

Filament Health Corp (OTCQB:FLHLF, NEO:FH) said Magdalena Biosciences, its joint venture (JV) with Jaguar Health, has initiated a preclinical study o more_horizontal

Filament Health says Health Canada authorizes Phase 2 clinical trial studying botanical psilocybin for opioid use disorder

By Proactive Investors
October 10, 2023

Filament Health says Health Canada authorizes Phase 2 clinical trial studying botanical psilocybin for opioid use disorder

Filament Health Corp (OTCQB:FLHLF, NEO:FH) told investors that Health Canada has approved a phase 2 clinical trial of its botanical psilocybin drug ca more_horizontal

Biotechs favor natural psychedelics due to possible ‘entourage effect'

By Proactive Investors
October 3, 2023

Biotechs favor natural psychedelics due to possible ‘entourage effect'

Biotechnology companies researching the therapeutic potential of various psychedelics are choosing to work with natural forms of these compounds deriv more_horizontal

Psychedelics M&A heating up as one drug nears FDA-approval

By Proactive Investors
September 29, 2023

Psychedelics M&A heating up as one drug nears FDA-approval

With MDMA on track to gain United States Food and Drug Administration (FDA) approval for the treatment of post-traumatic stress disorder (PTSD) in 202 more_horizontal

Filament Health announces non-brokered private placement

By Proactive Investors
September 29, 2023

Filament Health announces non-brokered private placement

Filament Health Corp (OTCQB:FLHLF, NEO:FH) told investors it intends to complete a non-brokered private placement for gross proceeds of up to C$2 mil more_horizontal

Filament Health targets substance use disorders with natural psychedelics

By Proactive Investors
September 26, 2023

Filament Health targets substance use disorders with natural psychedelics

Filament Health Corp (OTCQB:FLHLF)'s diversified business model makes it one of the only psychedelics companies to be already generating revenue.   more_horizontal

Filament Health's Magdalena Biosciences JV with Jaguar Health completes import of coca leaf from Peru

By Proactive Investors
September 20, 2023

Filament Health's Magdalena Biosciences JV with Jaguar Health completes import of coca leaf from Peru

Filament Health Corp (OTCQB:FLHLF) told investors that its Magdalena Biosciences joint venture (JV) with Jaguar Health has completed an import of coca more_horizontal


Search within

Pages Search Results: